Wuhan iRegene Therapeutics closes multimillion-yuan Pre-A round

On July 17, Wuhan iRegene Therapeutics announced the completion of a multi-million-yuan Pre-A round of financing, which was co-invested and completed by Renfu Industrial Fund and Huafang Capital.

On July 17, Wuhan iRegene Therapeutics announced the completion of a multi-million-yuan Pre-A round of financing, which was co-invested and completed by Renfu Industrial Fund and Huafang Capital.

Wuhan iRegene Therapeutics was established in August 2017, the core scientific team from the university of Cambridge and the Roslin Institute.

The company aims to develop a variety of cellular therapeutic drugs to contribute to the regenerative medicine treatment of central neuron system diseases, especially neurodegenerative diseases, like Parkinson’s disease.

Therefore, it focuses on the development of in vitro regenerative system of central neural stem cells and new clinical schemes for disease treatment.

Wuhan iRegene Therapeutics has carried out a number of international and domestic cooperation.

The partners and clients include John Van Geest Centre for Brain Repair, university of Cambridge, cancer research center, university of Bath, Cardiff university and many Chinese biomedical enterprises.

Wuhan iRegene Therapeutics aims to deepen the team’s research and development capabilities through horizontal cooperation and expand overseas markets.

In the meantime, the company has carried out close cooperation with large comprehensive hospitals in China for the purpose of clinical trials of cell drugs.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/20/wuhan-iregene-therapeutics-closes-multimillion-yuan-pre-a-round/.

Leave a Reply

Please Login to Comment